Unprecedented Advances in Treating Multiple Myeloma With BCMA-Targeted Agents, Featuring a Patient Perspective

Unprecedented Advances in Treating Multiple Myeloma With BCMA-Targeted Agents, Featuring a Patient Perspective is organized by Pharmacy Times Continuing Education (PTCE).,Release date: May 10, 2022,Expiration date: May 10, 2023,Description:,Though the treatment and management of multiple myeloma (MM) has evolved with the introduction of new therapies, a large proportion of patients continue to experience treatment failure or have a short duration of response to treatment. Targeting B-cell maturation antigen (BCMA) has emerged as a potential therapeutic target in the MM treatment landscape, with 2 different FDA-approved modalities currently available and others under investigation. This program will guide specialty and managed care pharmacists involved in the care of patients with MM to make clinical decisions for the choice of BCMA-targeted agent based on disease- and patient-specific factors. The discussion will also explore the potential adverse effects of BCMA-targeted therapies and the pharmacist’s role in adverse effect monitoring and management. This activity features a Patient Perspective interview, offering pharmacists important insight into the patient’s journey and experience from diagnosis to treatment.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Examine the role of BCMA as a therapeutic target for relapsed/refractory multiple myeloma,• Analyze current and emerging clinical data for the treatment of multiple myeloma with BCMA-targeted therapies,• Identify potential adverse effects associated with BCMA-targeted therapies to effectively monitor and manage patients,• Investigate strategies for the cost-effective use of BCMA-targeted therapies in the treatment of multiple myeloma